H S Kuo1, H J Chang, P Chou, L Teng, T H Chen. 1. Graduate Institute of Public Health, College of Medicine, National Yang-Ming University, Taipei, Taiwan.
Abstract
BACKGROUND: The high prevalence and severe consequences of non-insulin dependent diabetes mellitus (NIDDM) in Taiwan calls for urgent measures to detect this disease in the asymptomatic phase. However, the efficacy of early detection of NIDDM is highly dependent on its natural history from the disease-free state, through the asymptomatic to the symptomatic phase and death from NIDDM or other causes. METHODS: In order to project the above progression, a five-state illness-and-death Markov chain model was proposed to estimate these transition parameters using data from two rounds of a blood sugar screening programme for NIDDM in Puli, in central Taiwan. RESULTS: Results showed that the annual incidence for asymptomatic NIDDM was 10.67 per 1000 (95% CI: 8.26-13.79) and the average duration between the asymptomatic and symptomatic phases (the sojourn time) was 8 years (95%CI: 5.74-11.29). The 10-year survival rate for asymptomatic NIDDM (79.35%) was better than that for symptomatic NIDDM (69.45%). Prediction of deaths from NIDDM was performed to assess how the efficacy of screening for NIDDM varied by different screening frequencies (annual, biennial, 4-yearly and the control group). Results indicated there is no substantial difference in mortality reduction from NIDDM among the annual, biennial and 4-yearly screening regimens. However, a 4-yearly screening regimen significantly reduced deaths from NIDDM by 40% (95% CI: 26-51%). CONCLUSIONS: A long sojourn time and the substantial reduction in mortality suggest that a 4-yearly screening regime for NIDDM would be most effective and feasible in Taiwan. The proposed five-state Markov chain model can be applied to other similar NIDDM screening projects.
BACKGROUND: The high prevalence and severe consequences of non-insulin dependent diabetes mellitus (NIDDM) in Taiwan calls for urgent measures to detect this disease in the asymptomatic phase. However, the efficacy of early detection of NIDDM is highly dependent on its natural history from the disease-free state, through the asymptomatic to the symptomatic phase and death from NIDDM or other causes. METHODS: In order to project the above progression, a five-state illness-and-death Markov chain model was proposed to estimate these transition parameters using data from two rounds of a blood sugar screening programme for NIDDM in Puli, in central Taiwan. RESULTS: Results showed that the annual incidence for asymptomatic NIDDM was 10.67 per 1000 (95% CI: 8.26-13.79) and the average duration between the asymptomatic and symptomatic phases (the sojourn time) was 8 years (95%CI: 5.74-11.29). The 10-year survival rate for asymptomatic NIDDM (79.35%) was better than that for symptomatic NIDDM (69.45%). Prediction of deaths from NIDDM was performed to assess how the efficacy of screening for NIDDM varied by different screening frequencies (annual, biennial, 4-yearly and the control group). Results indicated there is no substantial difference in mortality reduction from NIDDM among the annual, biennial and 4-yearly screening regimens. However, a 4-yearly screening regimen significantly reduced deaths from NIDDM by 40% (95% CI: 26-51%). CONCLUSIONS: A long sojourn time and the substantial reduction in mortality suggest that a 4-yearly screening regime for NIDDM would be most effective and feasible in Taiwan. The proposed five-state Markov chain model can be applied to other similar NIDDM screening projects.
Authors: R K Simmons; M Rahman; R W Jakes; M F Yuyun; A R Niggebrugge; S H Hennings; D R R Williams; N J Wareham; S J Griffin Journal: Diabetologia Date: 2010-10-27 Impact factor: 10.122
Authors: G C Kabat; W Y-Y Wu; J W Bea; C Chen; L Qi; M L Stefanick; R T Chlebowski; D S Lane; J Wactawski-Wende; S Wassertheil-Smoller; T E Rohan Journal: Int J Obes (Lond) Date: 2016-10-17 Impact factor: 5.095
Authors: L A Sargeant; R K Simmons; R S Barling; R Butler; K M Williams; A T Prevost; A L Kinmonth; N J Wareham; S J Griffin Journal: Diabet Med Date: 2010-09 Impact factor: 4.359
Authors: Justin B Echouffo-Tcheugui; Rebecca K Simmons; Kate M Williams; Roslyn S Barling; A Toby Prevost; Ann Louise Kinmonth; Nicholas J Wareham; Simon J Griffin Journal: BMC Public Health Date: 2009-05-12 Impact factor: 3.295
Authors: Rebecca K Simmons; Justin B Echouffo-Tcheugui; Stephen J Sharp; Lincoln A Sargeant; Kate M Williams; A Toby Prevost; Ann Louise Kinmonth; Nicholas J Wareham; Simon J Griffin Journal: Lancet Date: 2012-10-04 Impact factor: 79.321